

Contents

Preface	xxxvii
About the Editors	xliii
About the Authors	xlvi

Chapter One

Introduction to Biotechnology and the Law 1

Robert F. Copple and Hugh B. Wellons

A. The Biotech Primer	4
B. Biotech Defined	5
1. Three-Branch Approach	6
C. The Biotech Company Life Cycle	6
1. Phase I: Startup	7
a. Intellectual Property	7
b. Company Formation	8
c. Investment Capital	8
2. Phase II: Early Development	9
a. Additional Investment	9
b. The Regulatory Track	10
c. Business Growth and Complexity	10
3. Phase III: Later Stage Development and Product Approval	11
4. Phase IV: Challenges Facing the Now Mature Company	11
a. Commercialization	12
b. Regulatory Oversight	12
c. Litigation	13
D. Conclusion	13

Chapter Two

Managing Innovation: Patent Basics for Biotechnology Counsel 15

Margaret J. Sampson and Michelle M. LeCointe

A. Introduction to Patents	15
B. U.S. Patent Portfolios	16
1. Introduction	16

2.	Changes to the U.S. Patent System	20
a.	Patent Term	20
b.	The America Invents Act	21
3.	What Is—and Is Not—Patentable?	23
a.	Laws of Nature	24
b.	Abstract Ideas	26
4.	Requirements for Patentability—New, Useful, and Nonobvious	28
a.	Novel	28
b.	Nonobvious	28
c.	Utility	29
d.	Other Requirements	29
5.	Patent Application Process	30
a.	Types of U.S. Patents	30
b.	Provisional Applications	31
c.	Utility and Patent Cooperation Treaty Patent Applications	32
d.	Preparing the Patent Application	33
e.	Filing the Patent Application	36
f.	Publication of Patent Applications	41
g.	Patent Prosecution	41
6.	Post-Issue Patent Considerations	46
a.	Maintenance Fees	46
b.	PTAs and Extensions	46
c.	Corrections to the Patent	47
d.	Additional Patent Applications	48
e.	Post-Issue Patent Challenges	50
C.	Foreign Patent Portfolios	51
1.	Protection Strategy	52
2.	Patentability Differences	55
3.	Other Considerations	57
4.	Prerequisites to Filing	58
5.	Options for Filing in Other Jurisdictions	59
6.	Additional Considerations	65
D.	Managing the Company’s Patent Estate	65
1.	A Family Portrait	65
2.	Keeping It in the Family	67
3.	Skeletons in the Closet	70
a.	Rights of Ownership	71
b.	Correspondence to Products or Business Strategies	72
c.	Freedom to Operate	74

Chapter Three

Company Formation 77

Andrew T. Hoyne and Cortney E. Mendenhall

- A. Introduction 77
 - 1. “But Will It Help Us Get Money?” 77
 - 2. The Importance of the Board of Directors 78
 - 3. Speed 80
 - 4. Simplicity 81
 - 5. Founders 81
 - 6. Financing and Product Development Plan 82
 - 7. The Role of the Company’s Attorneys 83
- B. Biotechnology Company Models 83
 - 1. Company Formed before In-Licensing While Research and Development Continues at University 83
 - 2. Technology Flip 84
 - 3. Revenue-Funded Company 85
 - 4. Corporate Deal-Funded Company 85
 - 5. Holding Company and Series LLC 86
 - 6. Venture Fund-Launched Company 87
 - 7. Angel Investor-Funded Company 87
 - 8. Significant Self-Funded Company 88
 - 9. Shoestring Self-Funded Company 88
 - 10. Charitable Corporation or Foundation 89
 - 11. Debt-Funded Company 90
- C. Building a Strong Team 90
 - 1. Founders 91
 - 2. Board of Directors or Board of Managers 92
 - 3. Scientific Advisory Board 94
 - 4. Management 94
 - a. Chief Executive Officer 95
 - b. Chief Financial Officer 95
 - c. Chief Scientific Officer 96
 - d. Clinical/Regulatory 96
 - 5. Employees 97
- D. Entity Selection and Formation 99
 - 1. No Perfect Choice 99
 - 2. Sole Proprietorships and Partnerships 99
 - 3. C-corporations 100
 - a. Limited Liability 101
 - b. Centralized Management 102
 - c. Owners 102

d. Transferability of Ownership	102
e. Classes of Ownership	102
f. Incentive Compensation	103
g. Taxation	103
4. S-corporations	104
a. Shareholder Type	104
b. Shareholder Number	105
c. Shareholder Residency	105
d. Class of Stock	105
e. Other Considerations	105
5. LLCs	108
a. LLC Organization	108
b. Advantages	110
c. Problems Using an LLC	113
6. Exotic Entity Types	116
7. State of Incorporation or Organization	117
8. Name Selection	119
a. Trademark Search	119
b. Unique Name	119
c. Trademark Registration	120
d. Foreign Registration	120
e. State Corporate Law	120
E. Capital Structure and Stock Grants	120
1. Introduction	120
2. Securities Law Compliance	121
3. Founders' Stock, Restricted Stock, and Stock Options	122
a. Grants or Sales of Stock	122
b. Restricted Stock	123
c. Warrants and Stock Options	124
4. Common and Preferred Stock	129
5. Convertible Debt	129
6. Simple Agreement for Future Equity	130
7. Series Seed Preferred Stock	130
F. Incubators	130
G. University Relationships	131
H. Early Stage Company Agreements	131
1. Brief Review of Intellectual Property for the Non-Intellectual Property Attorney	131
a. Patents	132
b. Trade Secrets	132
c. Trademarks	132
d. Copyrights	133
2. Confidentiality Agreements	133

3. Material Transfer Agreements 136
 4. Research Collaboration Agreements 138
 I. Positioning for an Exit 140

Chapter Four

Acquisition of Biotechnology—Technology Transfer 171

Hugh B. Wellons

A. Technology Creation 172
 1. Protecting Propriety of the Invention in the Early Stages 172
 a. Confidentiality Agreements 172
 b. Who Was First? 173
 c. Company Records 174
 2. Keeping Necessary Records 175
 3. Who Owns What? (Employer versus Employee and
 Joint Venture Issues) 175
 a. Work Made for Hire 175
 b. Employee Rights 178
 c. State Laws 178
 d. Canadian and European Union Laws 179
 e. Trade Secrets 180
 f. Joint Venture Ownership 181
 4. Patent Filing: Protecting an Invention and Limiting Others' Use 182
 a. Why File a Patent? 182
 b. Patent Requirements 182
 c. Patent Claims and Rights 183
 d. Types and Stages of Patents 183
 e. Patent Prosecution 184
 f. Post-Issue Considerations 185
 g. Foreign Patent Filing 185
 5. Possible Effects of Outside Funding 185
 a. Ownership 185
 b. Public Domain 187
 c. Manufacturing or Sales Restrictions 187
 B. Forms of Technology Transfer 188
 1. Acquisition of Owner 188
 a. Acquiring the Owner 188
 b. Employing the Owner 189
 2. Assignment 189
 3. License and Sublicense 190
 a. Common Form of Transfer 190
 b. Alternative to Assignment 190
 c. Sublicense 191

4.	Fair Use Agreement	192
a.	Fair Use and Experimental Use	192
b.	Fair Use Agreements	194
c.	Doctrine and Agreements' Effect on IP Ownership and Due Diligence	194
5.	Public Domain	195
C.	Typical Considerations of the Licensor	196
1.	Having Incentives to Disclose Inventions	196
2.	Considering First to Invent versus First to File	196
3.	Deciding Whether to License to Startups versus Established Companies	197
4.	Emerging and Early Stage of Technology	197
5.	Reimbursing the Cost of IP Protection	198
6.	Disconnect between Universities/Nonprofits and Industry with IP Rights Arising from Sponsored Research	198
7.	Education of Faculty and Staff Regarding IP Issues	199
8.	Free or One-Size-Fits-All Models for Technology Licensing	199
9.	Additional Considerations	200
a.	Assignment	200
b.	Royalties	200
c.	Confidence in Licensee	200
d.	Reimbursement of Patent Costs	200
e.	Consultation/Say-So in Approving Sublicensees	200
f.	Statement Licensee Will Not Sue	201
g.	Requirement That Sublicensees Are Subject to License Terms	201
h.	Who Is on the Hook?	201
i.	Indemnification	201
j.	Minimal Representations and Warranties	201
k.	Sufficiency of Insurance	201
l.	Trademark Protection	202
m.	Original Missions	202
n.	Due Diligence Milestones and Fair Return Targets to Satisfy Bayh-Dole Act	202
o.	Reporting	202
p.	Sponsored Research Opportunities	202
D.	Transfer from Academia	202
1.	University Considerations	202
a.	Considerations of Employee/Researcher	205
b.	Considerations of Community and Society (and Also, Sometimes, the University)	206
2.	Material Transfer Agreements	207
3.	Principal Investigator Considerations	208
a.	Conflict of Interest and Conflict of Commitment	208
b.	Conflict of Interest	209

c.	Conflict of Commitment	209
d.	Special Knowledge	210
4.	Licensee Considerations	210
a.	Policies and Procedures	211
b.	It Is a Long Way to Market, So Wrap Up the People You Need	211
c.	Public Disclosure?	212
d.	Stakeholders	212
5.	Interests of Other Stakeholders	213
a.	Other Underwriters	213
b.	Government Agencies	213
c.	Special Government Considerations	214
d.	Nonprofits	214
6.	Common Restrictions	215
a.	License Only, Not an Assignment	215
b.	Time Limitations	215
c.	Restrictions on Participation by the Inventors	215
d.	Audit	215
e.	Scope of License	216
f.	Indemnification	216
g.	Sublicense Approval	216
h.	Sublicensee Subject to License Terms	216
i.	Original Licensee Always Liable	216
j.	Cannot Use the Name of the University	216
k.	Government Has a License	216
l.	Other Restrictions	216
7.	Common Guidelines for Price and Provisions of the License	217
a.	Standstill Fee	217
b.	Up-Front License Fee	217
c.	Minimum Annual Payments	217
d.	Periodic Licensing Fees (Such as Quarterly or Annual)	217
e.	Participation in Third-Party Payments	217
f.	Lump Sum Royalties	218
g.	Milestone Payments	218
h.	Sales-Based Royalties	218
i.	Equity in the Licensee	218
j.	Equity Protections	218
k.	Put of Shares	218
l.	A Time for Sale	219
8.	When Equity Is the Primary Consideration for the License	219
a.	Equity	219
b.	Activity	220
9.	Applicability of Bayh-Dole Act	220
a.	Written Employee Agreements	220
b.	Royalty Sharing	221

c.	Reporting	221
d.	U.S. Manufacturing	221
e.	United States Retains License	221
f.	License Only, No Assignment?	221
g.	Termination of License If Commercialization Is Inadequate	222
h.	Other Considerations	222
10.	Application of “CREATE” Act of 2004	223
11.	Conflict between Publication and Protection of IP	224
a.	Academicians Want to Publish	224
b.	Licensee Due Diligence	224
E.	Transfer from Other Nonprofit Entities	225
1.	Implications of Nonprofit Status	225
2.	Unrelated Business Income Tax	225
3.	Priorities of Nonprofit Technology Owner	226
4.	Joint Venturing (Especially Qualification for STTR Grants)	227
a.	SBIR Grants	227
b.	STTR Grants	227
c.	Problems with STTR and SBIR Grants	228
5.	Common Misconceptions	228
F.	Transfer from Individuals	229
1.	Consideration of Terms	229
a.	Parties	229
b.	Recitals	229
c.	Definitions	229
d.	Property Licensed	229
e.	Scope of the Assignment or License	230
f.	Territory	231
g.	Right to Sublicense	231
h.	Follow-on and Later-Developed Technology	231
i.	Term and Renewal of License	231
j.	Termination	232
k.	Deliveries	232
l.	Retention of Rights	232
m.	Payments	232
n.	Audit Rights	233
o.	Reporting and Marketing Responsibility	233
p.	Representations and Warranties of the Inventor	233
q.	Indemnification	234
r.	IP Protection	234
s.	Insurance	234
t.	Assignability	234
u.	Amendments	234

v. ADR	235
w. “Boilerplate” Language	235
2. Common Negotiation Points	235
a. Price Paid/Consideration	235
b. Fees and Royalties Are Both Negotiable Points	236
c. Records and Reporting	236
d. Warranty	236
e. Indemnification	237
f. IP Matters	237
g. Confirmation of Ownership	238
3. Patent Filing	238
G. Summary—What We Learned in Kindergarten	239

Chapter Five

Financing a Biotech Company 241

Bill Wofford and Ken Maready

A. Overview	242
1. Drug Development Costs	243
2. Product Development Time Lines	245
B. Basic Securities Law Considerations	247
1. Registration or Exemption under the Securities Act	247
2. Section 4(2) Exempt Transaction	248
3. Regulation D Exempt Transaction	249
4. New Section 4(6) “Crowdfunding” Exempt Transaction	252
5. Rule 701—Compensation Plans	255
6. State “Blue Sky” Laws	255
C. Pre-Seed and Seed Capital	256
1. Founders’ Stock	257
a. Restrictions on Transfer	259
b. Vesting	259
c. Lock Up	259
d. Drag Along	260
2. Employee Stock	261
a. Plan Basics	261
b. Securities	262
c. Tax	263
d. Corporate	264
e. Commercial	264
3. Stock to Service or Technology Providers	265
a. Securities	266
b. Tax	266
c. Conflicts of Interest	267

4.	Friends and Family	268
a.	Securities	268
b.	Corporate	268
5.	Crowdfunding	269
a.	Securities	269
b.	Corporate	270
c.	Commercial	270
6.	Angel Investors	271
a.	Securities	272
7.	Loans	273
8.	Generating Revenues to Reduce or Defer Need for Investment	273
a.	IP	274
b.	Commercial	274
9.	Government Funding	274
a.	SBIR Grants	275
b.	STTR Grants	276
c.	Advantages to Receiving Federal Grant Funding	277
d.	Disadvantages to Receiving Federal Grant Funding	277
e.	Eligibility/More Than 50 Percent Rule	278
f.	State Resources	280
D.	Venture Capital	280
1.	Financial Rights	282
a.	Valuation	282
b.	Liquidation Preference	282
c.	Participating Preferred	283
d.	Accruing Dividends	283
e.	Protection of Ownership Percentage	283
2.	Governance Rights	284
a.	Board Representation	284
b.	Protective Provisions/Class Voting	285
3.	Exit Rights	285
a.	Registration Rights	286
b.	Redemption Rights	286
c.	Co-Sale Rights	286
4.	Pay-to-Play Provisions	287
5.	Series B—Time to Start All Over	287
E.	Corporate Investment	288
F.	Philanthropic or Social Investing	290
G.	IPO	291
H.	Post-IPO Financing	294
1.	Private Investments in Public Equity	294
2.	Convertible Debt	295
3.	Project Finance	296
I.	Conclusion	297

Appendix A: Glossary of Frequently Used Basic Equity, Venture Capital,
and Securities Law Terms 298

 Basic Equity Terms 298

 Venture Capital Terms 300

 Securities Law Terms 305

Chapter Six

Employment Issues for Biotechnology Companies311

Jeffrey A. Van Doren

A. Employment at Will 311

B. Employee or Independent Contractor 312

 1. The Common Law Control Test 313

 2. The IRS 20-Factor Test 314

 3. New IRS Guidance 315

 a. Behavioral Control 316

 b. Financial Control 316

 c. Relationship 317

 4. The Economic Reality Test 317

 5. Potential Liability 319

C. Employer Coverage under Federal Civil Rights Laws 321

 1. Title VII of the Civil Rights Act of 1964
 (42 U.S.C. § 2000e et seq.) 321

 a. Basic Coverage 321

 b. Sexual Harassment 322

 2. ADEA (29 U.S.C. § 621 et seq.) 322

 a. Basic Coverage 322

 b. Older Workers Benefit Protection Act 323

 3. ADA (42 U.S.C. § 12101 et seq.) 323

 a. Basic Coverage 323

 b. Reasonable Accommodation 324

 4. Equal Pay Act (29 U.S.C. § 206(d)) 324

 5. Genetic Information Nondiscrimination Act of 2008
 (Pub. L. No. 110-233, 122 Stat. 881) 324

D. Employer Coverage under State and Local Civil Rights Laws 325

 1. State Civil Rights Law 325

 2. Local Laws and Ordinances 325

E. Equal Opportunity and Affirmative Action Obligations
of Government Contractors and Subcontractors 325

F. Other Federal Employment Laws 326

 1. FLSA (29 U.S.C. § 201 et seq.) 326

 a. Basic Coverage 326

 b. Basic Requirements 327

 c. Overtime Exemptions 328

d. Child Labor	331
e. Recordkeeping	331
2. FMLA (29 U.S.C. § 2601 et seq.)	331
3. NLRA (29 U.S.C. § 151 et seq.)	332
a. Coverage of the NLRA	332
b. Employee Rights under the NLRA	332
c. “Protected Concerted Activity”	333
d. Union Organizing	333
e. NLRA Applicability to Nonunion Employers	334
4. ERISA (29 U.S.C. § 1001 et seq.)	336
5. Occupational Safety and Health Act (29 U.S.C. § 651 et seq.)	336
6. Immigration Reform and Control Act of 1986 (18 U.S.C. §§ 274A–274C)	337
7. Uniformed Services Employment and Reemployment Rights Act of 1994 (38 U.S.C. § 4301 et seq.)	338
8. Fair Credit Reporting Act (15 U.S.C. § 1681 et seq.)	338
a. Written Notice and Authorization	339
b. Adverse Actions Procedures	339
9. Employee Polygraph Protection Act (29 U.S.C. § 2001 et seq.)	340
10. The Affordable Care Act—Nursing Mothers (29 U.S.C. § 207(r))	340
G. Use of Employment Contracts	340
1. When Is an Employment Agreement Useful?	340
a. Security	341
b. Recruitment Incentive	341
c. Defined Performance Expectations	341
d. Defined Compensation Expectations	341
e. Confidentiality and Intellectual Property Ownership	341
2. Items to Be Covered	342
a. Duration	342
b. Position and Title	343
c. Compensation	343
H. Employee Handbooks	352
1. Pros and Cons of Using	352
a. Reasons for Using	352
b. Reasons for Not Using	353
2. Items to Be Covered	354
a. Disclaimers and At-Will Statements	354
b. EEO Policies	354
c. Harassment Policy	354
d. Family and Medical Leave Policy	355
e. E-mail, Computer Usage, and Social Media Policies	355
f. Description of Benefits	356
g. Discipline Policy	356

I. Immigration Options for Biotech Employees	357
1. Obtaining a Visa and U.S. Entry	357
2. Nonimmigrant Visas	359
a. H-1B “Specialty Worker” Visa	359
b. TN “NAFTA Professional” Visa	361
c. L-1 “Intracompany Transfer” Visa	362
d. E-1 “Treaty Trader” and E-2 “Treaty Investor” Visas	363
e. E-3 Visa for Australian Professionals	364
f. O-1 “Extraordinary Ability Alien” Visa	365
g. F-1 Student Visa and Practical Training	366
3. Immigrant Visas and Permanent Residence Status	368
a. EB Preferences	369
b. Visa Backlogs and Priority Dates	371
c. Labor Certification	371
d. Immigrant Visa and Adjustment of Status	373

Chapter Seven

Regulation of Preclinical Research 375

Daniel T. Pancamo

A. Introduction	375
B. Animal Use in Biomedical Research and Testing	376
1. The Basic Regulatory Scheme—The Animal Welfare Act and Regulations	376
a. Overview of the AWA	376
b. Overview of the AWA Regulations	379
c. Implementation and Enforcement of the AWA and the AWA Regulations by APHIS	387
2. U.S. Government Principles for the Utilization and Care of Vertebrate Animals Used in Testing, Research, and Training	388
3. Memorandum of Understanding among APHIS, the Food and Drug Administration, and the NIH	389
4. NIH Considerations	390
a. Health Research Extension Act	390
b. NIH Extramural Research	391
c. <i>Guide for the Care and Use of Laboratory Animals</i> and <i>Institutional Animal Care and Use Committee Guidebook</i>	392
d. NIH Policies Regarding the Use of Chimpanzees in Research	393
5. FDA Considerations and Good Laboratory Practices	395
6. CDC Considerations	397
7. State Law	398
8. Conclusion	398

C. Other Regulatory Schemes Applicable to Preclinical Research—	
Protection of the Environment and Public Health	398
1. Introduction	398
2. EPA Jurisdiction and the Resource Conservation and Recovery Act	399
3. Applying Environmental Law to Academic Research Facilities	402
4. IACUC Responsibility	403
5. The Public Health Security and Bioterrorism Preparedness and Response Act of 2002 and Select Agents and Toxins	403
D. Other Regulatory Schemes Applicable to Preclinical Research—	
Occupational Safety and Health Considerations and the Protection of Individuals Conducting Preclinical Research	407
1. Introduction	407
2. OSHA Regulation, Standards, and Resources	407
3. Selected Resource Tools—Chemicals and Biohazards	409
4. Radioactive Materials in the Research Setting	410
E. Conclusion	410
Key Acronyms Used	411

Chapter Eight

Research and Development Collaborations 413

Eileen Smith Ewing and Hugh B. Wellons

A. Introduction: The Collaborator as Biotechnology’s White Knight	413
B. Finding a Strategic Partner: Beating the Mathematical Odds	415
1. Don’t Expect Big Pharma to Find You	417
2. It’s About the Science	417
3. Approaching Big Pharma with an Opportunity to Collaborate	418
4. Use of Third Parties as Valuable Contacts	418
C. Negotiating a Term Sheet	419
1. The Importance of the Term Sheet to the Transaction	419
2. Issues Crucial to Address at the Term Sheet Stage	420
3. Issues to Avoid Negotiating at the Term Sheet Stage	421
D. Key Issues in a Research Collaboration Agreement	422
1. Governance of the Research Collaboration	422
a. Composition of the Joint Steering Committee	422
b. Duties of the Joint Steering Committee	423
c. Meetings of the Joint Steering Committee	423
d. Decision Making by the Joint Steering Committee	424
2. The Scope of the Collaboration	424
a. Field	425
b. Scope Limitations Based on Patent Family	426

c.	Scope Limitations Based on Timing	426
d.	Scope Limitations Based on Project Funding	426
3.	IP	427
a.	Core IP of the Target, Developed Prior, but Highly Relevant, to the Collaboration	427
b.	Core IP of the Larger Funding Partner, Developed Prior, but Highly Relevant, to the Collaboration	428
c.	Background IP of the Target, Developed Prior to the Collaboration but of Possible Utility	428
d.	Background IP of the Larger Funding Partner, Developed Prior to the Collaboration but of Possible Utility	429
e.	IP Developed by One or Both Parties Arising out of the Collaboration	429
f.	IP Developed by the Target during, but outside of, the Collaboration	429
g.	Novel IP Developed by One or Both Parties during the Collaboration That Does Not Arise out of the Existing IP of Either Party	430
4.	License Grants	430
a.	Research Licenses	431
b.	Development and Commercialization Licenses	431
c.	Cross-Licenses; Freedom to Operate	431
d.	Enabling Licenses	432
e.	License as Protection against Infringement Claims	432
f.	Protect the IP against a Later Attack on the Patents	432
5.	Financial Terms	433
a.	Signature Payments	433
b.	Research Funding	434
c.	Equity Investments	434
d.	Milestone Payments	437
6.	Option to Develop and Commercialize	438
a.	Notice of Exercise	439
b.	Right of First Refusal	439
c.	Right of First Negotiation	440
d.	Rights in Unoptioned IP	440
7.	Term and Termination	442
a.	Term	442
b.	Early Termination	442
E.	Post-Closing Pitfalls That Can Derail an R&D Collaboration	443
1.	Change in Strategic Fit or Commitment to the Project	443
2.	Communication and Control Issues	444
3.	Unrealistic Expectations	444

F. Alliances with Third Parties—Keeping Other Options Open	444
1. Right of First Refusal May Preclude Other Transactions	446
2. Right of First Negotiation May Also Have a Chilling Effect	446
3. The Deal May Be Worth It; Rely on Contractual Protections	446
G. Conclusion: Where Do the Parties Go from Here?	447

Chapter Nine

Federal Regulation of Clinical Research 449

Erika Lietzan, Afia Asamoah, and Linda McCarty

A. Background	450
1. The Role of Clinical Research	450
2. Government Entities That Regulate Clinical Research	452
a. HHS: FDA	452
b. HHS: Office for Human Research Protections	453
c. HHS: NIH	453
d. HHS: Office of Civil Rights	454
e. HHS: CMS	455
f. HHS: Office of Inspector General	456
g. DOJ	456
h. The States	457
B. The Roles and Responsibilities of the Parties	458
1. Subject	458
2. Sponsor	458
3. PI	458
4. CRO	459
5. Monitor	460
6. IRB	460
7. Data Monitoring Committee	461
8. Institutional Biosafety Committee	461
C. Premarket Clinical Trial Process	462
1. Drug Trials	462
a. Exploratory INDs (Phase 0 Trials)	462
b. Phases I–III	463
2. Device Trials	463
3. Prior to Start of Clinical Trial	464
a. Designing the Clinical Trial	464
b. Selecting Qualified Investigators	467
c. Obtaining IRB Review and Approval	468
d. Obtaining Informed Consent from Subjects	468
e. Submitting an IND or IDE	471
f. Registering the Trial	475

4.	Conducting the Trial	476
a.	Reporting, Auditing, and Recordkeeping	476
b.	Terminating an IND or IDE	481
5.	After the Trial	483
a.	Study Close Out	483
b.	Clinical Trial Results Posting	484
c.	Other Dissemination of Clinical Trial Results	485
D.	Enforcement	486
1.	FDA Inspections	486
2.	Form 483 Observations	487
3.	Warning and Untitled Letters	488
4.	Administrative Consequences	489
5.	Civil and Criminal Liability	491
E.	Other Issues	491
1.	Postmarket Trials	491
a.	Phase IV Commitments	491
b.	Trials Required Pursuant to Section 505(o)	492
c.	Deferred Pediatric Studies	493
d.	Studies to Support Pediatric Exclusivity	493
e.	Voluntary Research to Support New Conditions of Use	494
f.	Investigator-Initiated Trials	494
2.	Sites and Trials in Foreign Countries	494
3.	Expanded Access	496
a.	Drugs and Biologics	496
b.	Devices	498
	Key Acronyms Used	500

Chapter Ten

Privacy Issues for Biotechnology Companies 501

Rebecca Frigy Romine

A.	Introduction	501
1.	Overview of Relevant Privacy Laws	501
2.	How Do HIPAA and the Privacy Laws Apply to Biotechnology Companies?	503
B.	HIPAA, the Privacy Rule, the Security Rule, the Breach Notification Rule, and the Health Information Technology for Economic and Clinical Health Act	504
1.	Basic Overview and Important Definitions	504
a.	Statutory and Regulatory Background	504
b.	Important Definitions	505

2.	Individual Rights	509
a.	Notice of Privacy Practices (45 C.F.R. § 164.520)	510
b.	Restriction of PHI by Individuals (45 C.F.R. § 164.522(a))	510
c.	Access to PHI by Individuals (45 C.F.R. § 164.524)	511
d.	Amendment or Change of PHI (45 C.F.R. § 164.526)	512
e.	Accounting of Disclosures (45 C.F.R. § 164.528)	513
f.	Complaints (45 C.F.R. § 160.306)	515
3.	Permissible Uses and Disclosures of PHI That Do Not Require Authorization	515
a.	Uses and Disclosures for Treatment, Payment, and Health Care Operations (45 C.F.R. § 164.506(c))	516
b.	Uses and Disclosures for Fund-Raising Activities (45 C.F.R. § 164.514(f))	516
c.	Disclosures Required by Law (45 C.F.R. § 164.512(a))	517
d.	Disclosures for Public Health Activities (Including Child Abuse Reporting) (45 C.F.R. § 164.512(b))	517
e.	Disclosures for Victims of Abuse, Neglect, or Domestic Violence (45 C.F.R. § 164.512(c))	518
f.	Disclosures for Health Oversight Activities (45 C.F.R. § 164.512(d))	519
g.	Disclosures for Judicial and Administrative Proceedings (45 C.F.R. § 164.512(e))	519
h.	Disclosures for Law Enforcement Purposes (45 C.F.R. § 164.512(f))	521
i.	Disclosures about Decedents to Coroners, Medical Examiners, and Funeral Directors (45 C.F.R. § 164.512(g))	521
j.	Uses and Disclosures for Cadaveric Organ, Eye, or Tissue Donation Purposes (45 C.F.R. § 164.512(h))	521
k.	Uses and Disclosures for Research Purposes (45 C.F.R. § 164.512(i))	521
l.	Disclosures to Avert a Serious Threat to Health or Safety (45 C.F.R. § 164.512(j))	525
m.	Disclosures for Specialized Government Functions (45 C.F.R. § 164.512(k))	526
n.	Disclosures for Workers' Compensation (45 C.F.R. § 164.512(l))	526
4.	Business Associates	526
a.	Disclosures to Business Associates (45 C.F.R. § 164.502(e)(1)(i))	526
b.	BAAs (45 C.F.R. § 164.504(e))	527
c.	Direct Liability of Business Associates	529

5. Uses or Disclosures That Require Authorization	530
a. Uses and Disclosures for Marketing (45 C.F.R. § 164.508(a)(3))	530
b. Sale of PHI (45 C.F.R. § 164.502(a)(5)(ii))	532
6. Uses and Disclosures Requiring an Opportunity to Agree or Object (45 C.F.R. § 164.510)	533
7. HIPAA-Compliant Authorizations (45 C.F.R. § 164.508)	534
a. General Content	535
b. Defective Authorizations	535
c. Compound Authorizations	536
d. Conditioning Authorizations	536
e. Authorizations for Marketing and the Sale of PHI	537
8. More about Research	537
a. When Is an Authorization Required?	537
b. Research Authorization Requirements	537
c. Using a Limited Data Set for Research Purposes	540
9. Data Use Agreements	540
10. Notification of Breach Requirements	541
a. Obligations of a Covered Entity (45 C.F.R. § 164.404 et seq.)	543
b. Obligations of a Business Associate (45 C.F.R. § 164.410)	544
c. State Law Considerations	545
11. The Security Rule	547
a. Required Compliance by Business Associates	547
b. Safeguards (45 C.F.R. § 164.306)	547
12. State Law and Preemption Issues	549
13. Penalties for Violations of the Privacy Rule and the Security Rule	551
C. The Federal Common Rule and Federal Certificates of Confidentiality	552
1. The Common Rule and HIPAA	552
2. Federal Certificates of Confidentiality (42 C.F.R. Part 2a)	556
D. Canadian Privacy Legislation	557
E. General Data Protection Regulation	558
1. Consent	561
2. Security	563
3. Breach Notification	564
4. Data Protection Officers	565
5. Cross-Border Data Transfers	566
6. Other Requirements	566
7. Penalties	566
F. California Consumer Privacy Act of 2018	567
G. Privacy Shield Framework	569
Key Acronyms Used	573

Chapter Eleven**Medical Reimbursement 575***Paul W. Radensky, M.D., J.D. and Amy Hooper Kearbey, J.D.*

A. Introduction	575
B. Reimbursement Basics	576
1. Key Terms and Concepts	576
2. Coverage	576
a. Determining the Scope of Benefits	577
b. Checking for Specific Exclusions from Coverage	580
c. The Reasonable and Necessary Test	580
d. Medical Necessity for the Particular Patient	581
e. Implications of Coverage/Non-coverage	582
f. Coverage Process	582
3. Payment Law and Policy	583
4. Coding	584
5. Appeals	586
6. Who Are the Payers?	588
C. Applying the Basics	589
1. Coverage, Payment, and Coding for Drugs and Biologicals	589
2. Coverage, Payment, and Coding for Procedures Involving the Use of Medical Devices	591
3. Coverage Payment and Coding for DME, Prosthetics, Orthotics, and Supplies	593
4. Coverage, Payment, and Coding for In Vitro Diagnostics	594
D. Special Payment Rules for New Technologies	596
1. IPPS	596
2. OPSS	596
3. Ambulatory Surgical Centers—Payment for New Technology Intraocular Lenses	597
4. Private Payer Carve-Outs	597
E. Reimbursement for Investigational Products	598
1. NCD on Routine Costs of Qualifying Clinical Trials	598
2. Investigational Device Exemptions	599
F. Compliance Considerations	600
1. Requirements for Proper Billing	600
2. Reimbursement Support Services	602
3. Discounts and Related Fraud and Abuse Considerations	603
G. Conclusion	603
Key Acronyms Used	604

Chapter Twelve

Environmental Regulation of Biotechnology 607

Stephen A. Owens

- A. Introduction 607
- B. Regulation of Biotechnology under TSCA 613
 - 1. Summary of TSCA 613
 - 2. EPA’s TSCA Biotechnology Regulations 618
 - a. MCAN 619
 - b. Notice of Commencement of Manufacture or Import 624
 - c. Exemptions from the MCAN Requirement 624
 - 3. TSCA Experimental Release Application 627
 - 4. Test Marketing Exemption 630
 - 5. General Exemptions from the MCAN Requirement 632
 - a. Tier I Exemption 633
 - b. Tier II Exemption 634
- C. Biotechnology Regulation under FIFRA 635
 - 1. Review of Pesticide Registration Applications 635
 - 2. Data Requirements for Pesticide Registration Applications 637
 - 3. Field Tests of Genetically Engineered Pesticides 639
 - a. Experimental Use Permits 639
 - b. Information Required for EUP Applications 642
 - 4. Special Requirements for Biotechnology Pesticide Products 644
 - a. Biochemical Pesticides 644
 - b. Microbial Pesticides 645
 - c. Small-Scale Field Tests of Certain Genetically Modified Microbial Pesticides 647
 - d. PIPs 649
 - e. EUPs for PIPs 652
 - f. Gene Flow Assessment for PIPs 652
 - g. IRM 653

Chapter Thirteen

Approval of Biotechnology Products for Human Use 659

Areta Kupchyk and Snehal Trivedi

- A. Introduction 659
 - 1. Overview of the FDA Approval Process 659
 - a. Relevant Laws 660
 - b. Definitions 660

B. Standard Pathways to Market	666
1. Drugs: The Traditional New Drug Application	666
a. Standard for Approval	666
b. NDA Content and Format Requirements	668
c. NDA Classification Codes	669
d. Filing the NDA or BLA	670
e. Review of the NDA	671
f. Facility Inspection	672
g. Labeling Review	673
h. Advisory Committees	674
i. Completion of Review and Decision	675
j. Risk Evaluation and Mitigation Strategies	675
2. Drugs: The Faster 505(b)(2) Application	676
3. Biological Products	677
a. The BLA	677
b. Biosimilars	679
c. HCT/Ps	687
4. Medical Devices	689
a. Device Classifications	689
b. The 510(k) Notification Process	690
c. The PMA Process	691
d. Investigational Device Exemption	692
5. Combination Products	694
a. The Pathway	694
b. Primary Mode of Action	695
c. Center with Primary Jurisdiction	695
d. Single or Multiple Marketing Applications	696
e. Request for Designation	696
C. Expedited Pathways to Market	698
1. Fast Track	698
2. Breakthrough Therapies	700
3. Accelerated Approval	701
4. Priority Review	702
5. Rare Pediatric Disease Priority Review	702
6. Orphan Drug Designation	703
7. HUD	705
D. Future Pathways to Market	706
Key Acronyms Used	707

Chapter Fourteen

Agricultural Biotechnology Approval Processes 709

Thomas P. Redick

- A. Introduction 709
- B. U.S. Coordinated Framework 711
- C. Role of USDA 714
 - 1. Notification of Deregulation 714
 - 2. Permits for PMPs and Industrial Crops 715
- D. Role of EPA 716
 - 1. EPA Regulation of PIPs 716
 - 2. EPA Regulation of Agricultural Chemical Residues 717
- E. Role of FDA 720
- F. Regulation of Genetic Editing in Agriculture 723
 - 1. U.S. Regulatory Policy Evolving 723
 - 2. International Regulation of Genetic Editing in Agriculture 723
- G. Role of the States in Regulation of Biotech Crops 725
 - 1. State-Based Agricultural Management 725
 - a. Seed Purity Laws 725
 - b. GMO Labeling Movement and Federal Preemption 725
 - c. “Noxious” Weed Management 727
 - d. Managing the Economic Impact of Agricultural Biotechnology 727
 - e. EPA and the States 728
 - f. USDA and the States 728
 - g. FDA and the States 729
- H. Biotech Crop Regulation in Other Countries 729
 - 1. Argentina 730
 - 2. Brazil 730
 - 3. Canada 731
 - 4. China 732
 - 5. The EU 733

Chapter Fifteen

Federal and State Regulation after Approval 737

Areta Kupchyk

- A. Regulatory Authorities 737
 - 1. Food and Drug Administration 737
 - 2. Office of Inspector General, Department of Health and Human Services 739

3.	DOJ Civil Division	740
4.	Federal Trade Commission	740
5.	Securities and Exchange Commission	741
B.	Postapproval Responsibilities	741
1.	CGMP	742
a.	Drug and Biological Products	742
b.	Medical Devices	743
c.	FDA Inspections	743
d.	Mitigating Cybersecurity Risks Related to Networked Medical Devices	745
2.	Postapproval Reporting	746
a.	Product Problem Reports	746
b.	Adverse Experience Reports	748
c.	Annual and Periodic Reports	752
d.	Early Notification of Possible Drug Shortages	753
e.	Labeling Changes	753
3.	Import and Export Requirements	755
a.	Import	755
b.	Import for Export	755
c.	Export	756
4.	Regulation of Advertising and Labeling	758
a.	Key Terms	758
b.	Basic Principles	761
c.	Types of Advertisements	762
d.	Limitations on FDA Regulation of Advertising	764
e.	Off-Label Use and the Exchange of Scientific Information	765
f.	The Good Reprint Practice Guidance	767
g.	Proposed Guidance for Responding to Unsolicited Requests for Off-Label Information	769
h.	Guidance on Industry-Supported Scientific and Education Activities	770
i.	Guidance on Communication of Health Care Economic Information	772
C.	Withdrawal of FDA Approval	773
D.	False Claims Act	775
1.	The Neurontin Case (2004)	776
2.	The Serono Laboratories Serostim Settlement (2005)	776
3.	The Bristol-Myers Squibb Abilify Settlement (2007)	777
4.	The Cephalon Actiq, Gabitril, and Provigil Settlement (2008)	778
a.	Actiq	778
b.	Gabitril	779
c.	Provigil	779
5.	The AstraZeneca Seroquel Settlement (2010)	780

6. The Allergan Botox Settlement (2010)	781
7. The Abbott Laboratories Depakote Plea Agreement (2012)	782
8. The Amgen Aranesp Settlement (2012)	783
9. The Par Pharmaceuticals Megace ES Settlement (2013)	784
10. The J&J Risperdal Settlement (2013)	785
11. The Genzyme Septrafilm Settlement (2013)	786
12. Endo Pharmaceuticals (2014)	787
13. Astellas Pharma US Inc. (2014)	787
14. Shire Pharmaceuticals (2014)	788
15. NuVasive Inc. Settlement (2015)	789
16. Medtronic, Inc. Settlement (2015)	789
17. Warner Chilcott Plea Agreement (2015)	790
18. OtisMed (2015)	791
19. Acclarent Inc. Settlement (2016)	791
20. Aegerion Pharmaceuticals Inc. (2017)	792
21. Shire Pharmaceuticals LLC Settlement (2017)	793
22. Baxter Healthcare Corp. Settlement (2017)	794
23. Novo Nordisk Settlement (2017)	795
E. Anti-Kickback Statute and Other Illegal Remuneration	795
F. The Physician Payments Sunshine Act	796
Key Acronyms Used	797

Chapter Sixteen

Development and Commercialization Alliances 799

Eileen Smith Ewing and Hugh B. Wellons

A. Introduction: Why Choose to Partner?	799
B. Considerations in Choosing a Partner	800
C. The Stage of the Drug Candidate Will Define the Alliance	801
1. Early Stage Deals	802
a. Target Identification and Validation	802
b. Hits	803
c. Leads	803
d. Optimized Leads	803
2. Preclinical Stage Licensing	804
a. ADME/Tox Studies	804
b. Human Trials in Australia/China	804
c. Investigational New Drug Application	805
3. Clinical Stage Licensing	805
a. Phase I	805
b. Phase II	805
c. Clinical Trials (Phase III)	805
4. Prelaunch Licensing	806

D. The Development and Commercialization License Agreement	806
1. Nature and Scope of License Grant	806
a. Identifying the Subject Technology	807
b. The Rights Granted	807
c. Scope of Rights	809
d. Retained Rights of the Licensor	810
2. Consideration for the License Grant	811
a. Milestone Payments	812
b. Royalty Payments, Generally	813
c. Term of Royalty Payments	817
d. Punitive Reduction in Royalty Rates	818
e. Reduction in Royalty Rates for Third-Party Licenses	818
3. Other IP Issues	819
a. Responsibility for Patent Prosecution and Maintenance	819
b. Abandoned Jurisdictions	819
c. Ongoing Cooperation	819
d. Trademarks and the Like	820
e. Prosecution of Infringers	820
4. Cooperation of the Parties during the Regulatory Approval Process	821
5. Participation in the Upside	821
a. “Co-Rights”	821
b. Bulk Supply Rights	824
E. Anticipating Changes of Control of Either Party	824
1. Licensor Issues	824
2. Licensee Issues	825
3. Tailoring a Solution	825
F. Terminating the Agreement If the Alliance Fails	826
1. Material Breach by the Licensee	827
a. The Licensor’s Perspective	827
b. The Licensee’s Perspective	827
2. Material Breach by the Licensor	827
a. The Licensor’s Perspective	827
b. The Licensee’s Perspective	827
3. Termination without Cause	828
G. Conclusion: The Importance of Getting It Right	828

Chapter Seventeen

Patent Litigation and Dispute Proceedings Overview for the Non-Patent Attorney 829

Michelle G. Breit and Robert F. Copple

A. Introduction	829
-----------------------	-----

B. General Overview of Patent Litigation in Federal Court	831
1. Patent Infringement Defined	831
a. Direct Infringement (35 U.S.C. § 271(a))	832
b. Indirect Infringement (35 U.S.C. § 271(b), (c))	832
c. Literal Infringement and Doctrine of Equivalents	833
2. Proving Infringement	834
a. Claim Construction	834
b. Applying the Construed Claims to the Accused Product	837
C. Pre-Litigation Considerations	837
1. Prefiling Investigation	837
2. Whether to Send a Cease and Desist Letter	839
D. Litigation Procedure Overview	840
1. Choosing an Appropriate Forum	841
2. Choosing Appropriate Parties	843
3. Pleadings	845
a. Complaints	845
b. Defenses and Counterclaims	846
4. Remedies	864
a. Damages	865
b. Equitable Relief	871
c. Attorneys' Fees	871
E. General Overview of Post-Grant Proceedings before the USPTO	872
1. PGR	872
2. IPR	873
3. CBM Review	874
4. Ex Parte Reexamination	875
5. Derivation Proceedings	876
6. Director-Initiated Reexamination	877
7. Reissue	878
F. ADR	878
1. General ADR Considerations	878
2. Participation by Senior Management	879
3. Advantages of ADR Confidentiality	880
4. ADR as an Alternative to Foreign Litigation	881

Chapter Eighteen

The Impact of Bankruptcy 885

Craig B. Young

A. Introduction—Bankruptcy Basics	885
1. The Origin of Modern Bankruptcy Law	885
2. Bankruptcy Protection for Individuals	887

3. Bankruptcy Protection for Entities	889
4. Bankruptcy in Biotech Entities	890
B. A Primer on Creditors' Rights	891
1. Introduction	891
2. "Creditors' Rights"?	892
3. Secured Creditors	893
4. Unsecured Creditors	898
5. Creditors' Right to Representation	901
6. Debtor's Duty to Creditors	904
7. Credit versus Equity	908
C. Liquidation versus Reorganization	910
D. The Debtor's Bankruptcy Estate	914
E. The Automatic Stay	916
F. Contracts and Leases in Bankruptcy	918
1. Assumption of Executory Contracts	922
2. Rejection of Executory Contracts	923
3. Assignment of Executory Contracts	926
G. Sale of Property in Bankruptcy	931
H. Equity Holders in Bankruptcy	934
I. Conclusion	935

Chapter Nineteen

Risky Business: Litigation, Risk Management, and Dispute Control 937

Robert F. Copple

A. Introduction	937
B. The Biotech Lawyer as Dispute Manager	938
1. Dispute Management Provisions in Commercial Agreements and Documents	939
a. Indemnification Provisions and Limitations on Liability	940
b. Acquisition Hold Back Provisions	940
c. Record Retention and Control within the Deal	941
d. Alternative Dispute Provisions	941
2. Compliance Counseling	942
3. Early Claim Review and Response	942
4. Litigation	942
a. Choosing the Right Litigator and Firm	943
b. Litigation and Cost Control	943
c. Dual Track Strategies	944

C. Intellectual Property and Confidential Business Information	944
1. Trademark Issues	944
a. Registration and Protection	945
b. Litigation Claims—Infringement and Dilution	946
2. Trade Secrets	950
a. Trade Secrets Defined	950
b. Establishing the Foundation for Trade Secret Protection	951
c. Misappropriation	953
d. Inevitable Disclosure Doctrine	955
D. Products Liability	955
1. Defects and Causation	956
2. Establish a Record of Compliance and Responsibility	957
E. Business Liability	959
1. Corporate Disclosures and Insider Trading	959
a. Misstatements and Omissions	960
b. Insider Trading	960
2. Corporate Governance	961
3. False Claims and Whistleblowers	962
F. Document and Information Retention	963
1. Regulatory Recordkeeping Requirements	964
2. Litigation Discovery Issues	964
3. Data Management Policy	965
a. Identify the Objectives of the Enterprise	965
b. Minimalism and Control	966
c. Training and Simplicity of Procedures	966
d. Adequacy of Infrastructure	967
e. Information Security	967
f. Record Authenticity	967
g. Retrievability	967
h. Distribution Controls	968
i. Auditability	968
j. Consistency	969
k. Enforcement	969
G. ADR	970
1. ADR Defined	970
a. Arbitration	971
b. Mediation	972
2. ADR Myths and Misconceptions	973
a. A Sign of Weakness	973
b. Free Discovery	973

3. An Integrated Strategy for ADR 974
 - a. Before the Dispute Arises 974
 - b. In the Early Stages of the Dispute 975
 - c. Parallel Strategies 975
 - d. Private Forums and Confidentiality 976

Chapter Twenty

Bioethics 977

Gary E. Marchant, Robyn S. Shapiro, and Hugh B. Wellons

- A. What Is Bioethics? 979
 1. How Is Bioethics Different from Other Forms of Ethics? 979
 2. Approaches to Bioethics 980
 - a. Deontological 980
 - b. Utilitarianism 981
 - c. Virtue Ethics 981
 - d. Four Principle Approach 982
 - e. Casuistry 982
 3. Core Principles of Bioethics 983
 - a. Personal Autonomy 983
 - b. Beneficence/Nonmaleficence 983
 - c. Justice 984
 - d. Confidentiality 984
 4. History and Foundational Sources of Bioethics 985
 - a. Hippocratic Oath 985
 - b. Percival's Medical Ethics 985
 - c. Nuremberg Code 985
 - d. Belmont Report 986
 - e. Helsinki Declaration 986
 5. Relationship of Law and Bioethics 987
- B. Legal Contexts for Bioethics 987
 1. Constitutional Issues 987
 - a. Reproduction 988
 - b. Right to Die 992
 2. Special Focus on Research 993
 - a. Historical Context 994
 - b. U.S. Federal Regulations 995
- C. Case Studies 998
 1. Product Safety 999
 2. COIs 1000

3. Research Risks	1003
4. Informed Consent	1004
5. Disclosure versus Privacy: A Physician’s Duty to Disclose Patient Risks to a Third Party	1006
6. Autonomy	1008
7. Property Rights/Control of Your Body	1009
8. Conflicting Rights	1011
9. End-of-Life Issues	1012
10. Personhood/Respect	1013
11. Justice	1014
D. Conclusion	1015

Appendix A

Goat-Tech BioScience: A Legal/Biotech Case Study	1017
---	-------------

Appendix B

Biotechnology Resources	1021
--------------------------------------	-------------

Jennifer Korpacz Pelaia, J.D., M.S.L.S.

Appendix C

Patent & Technology License Agreement	1053
--	-------------

Background	1053
1. Definitions	1054
2. License Grant and Commercialization	1058
2.1 Grant	1058
2.2 Affiliates	1059
2.3 Sublicensing	1059
2.4 Diligent Commercialization	1060
3. Compensation	1061
3.1 Non-Royalty Payments Due from Licensee	1061
3.2 Royalties	1062
3.3 Minimum Royalties	1062
3.4 Non-cash Consideration	1063
3.5 Equity Consideration for License Grant	1063
4. Reports and Plans	1063
4.1 Quarterly Payment and Milestone Reports	1063
4.2 Annual Written Progress Report and Commercialization Plan	1064
4.3 Government and Economic Development Reporting	1065

5. Payment, Records, and Audits	1065
5.1 Payments	1065
5.2 Sales outside the U.S.	1066
5.3 Late Payments	1066
5.4 Records	1066
5.5 Auditing	1066
6. Patent Expenses and Prosecution	1067
6.1 Patent Expenses	1067
6.2 Direction of Prosecution	1068
6.3 Ownership	1068
6.4 Foreign Filings	1068
6.5 Withdrawal from Paying Patent Costs	1069
6.6 U.S. Patent and Trademark Office Entity Size Status	1069
7. Term and Termination	1069
7.1 Term	1069
7.2 Termination by Licensee	1069
7.3 Termination by Licensor	1070
7.4 Other Conditions of Termination	1070
7.5 Effect of Termination	1071
8. Confidentiality	1071
8.1 Definition	1071
8.2 Protection and Marking	1072
8.3 Confidentiality of Terms of Agreement	1072
8.4 Disclosure Required by Court Order or Law	1073
8.5 Copies	1073
8.6 Continuing Obligations	1073
8.7 Exclusions	1073
8.8 Copyright Notice	1074
9. Infringement and Litigation	1074
9.1 Notification	1074
9.2 Licensee's Enforcement Rights	1074
9.3 Licensor's Enforcement Rights	1074
9.4 Cooperation between Licensor and Licensee	1075
10. Export Compliance	1075
11. Representations and Disclaimers	1076
11.1 Licensor Representations	1076
11.2 Government Rights	1076
11.3 Licensor Disclaimers	1077
11.4 Licensee Representations	1077
12. Limit of Liability	1078
13. Indemnification	1078
13.1 Indemnification Obligation	1078
13.2 Conditions of Indemnification	1079

14. Insurance	1079
14.1 Insurance Requirements	1079
14.2 Evidence of Insurance and Notice of Changes	1080
15. Assignment	1080
16. Governmental Markings	1080
16.1 Patent Markings	1080
16.2 Governmental Approvals and Marketing of Licensed Products and/or Licensed Services	1081
16.3 Foreign Registration and Laws	1081
17. Use of Name	1081
18. Notices	1081
19. General Provisions	1082
19.1 Binding Effect	1082
19.2 Construction of Agreement	1082
19.3 Counterparts and Signatures	1083
19.4 Compliance with Laws	1083
19.5 Governing Law	1083
19.6 Modification	1083
19.7 Severability	1083
19.8 Third Party Beneficiaries	1084
19.9 Waiver	1084
19.10 Sovereign Immunity	1084
19.11 Entire Agreement	1084
19.12 Claims against Licensor for Breach of Agreement	1084
19.13 Grant of Security Interest	1085
20. No Other Promises and Agreements; Representation by Counsel	1085
21. Deadline for Execution by Licensee	1085
Index	1087